Nipro Corp
TSE:8086
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 081.5
1 470
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Nipro Corp
Nipro Corp
Cash & Cash Equivalents
Nipro Corp
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nipro Corp
TSE:8086
|
Cash & Cash Equivalents
¥83.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
1%
|
|
|
Hoya Corp
TSE:7741
|
Cash & Cash Equivalents
¥553B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
|
H
|
Hogy Medical Co Ltd
TSE:3593
|
Cash & Cash Equivalents
¥22.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-1%
|
|
|
Shofu Inc
TSE:7979
|
Cash & Cash Equivalents
¥9.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
|
Menicon Co Ltd
TSE:7780
|
Cash & Cash Equivalents
¥40.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Mani Inc
TSE:7730
|
Cash & Cash Equivalents
¥21.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
12%
|
|
Nipro Corp
Glance View
Nipro Corp. engages in the manufacture and sale of medical equipment, pharmaceutical products, and glass products. The company is headquartered in Osaka, Osaka-Fu and currently employs 35,251 full-time employees. The firm has three segments. The Medical-Related segment involves in the sale of injections and infusions, artificial organs, high function and dialysis related medical equipment, and diabetes, generics and kits related medicine products in Japan, as well as the sales of medical devices for injection and infusion, artificial organs and diabetes in overseas markets. The Pharmaceutical-Related segment involves in the manufacture and sale of pharmaceuticals. The Pharma Packaging segment sells glass for vials and ampoules as medical glass in Japan, thermos glass for lighting and glass for lighting equipment.
See Also
What is Nipro Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
83.6B
JPY
Based on the financial report for Jun 30, 2024, Nipro Corp's Cash & Cash Equivalents amounts to 83.6B JPY.
What is Nipro Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
1%
Over the last year, the Cash & Cash Equivalents growth was -5%. The average annual Cash & Cash Equivalents growth rates for Nipro Corp have been 3% over the past three years , -5% over the past five years , and 1% over the past ten years .
You don't have any saved screeners yet
